- Ken Shinomiya appointed as leader of Asahi Kasei's Healthcare Sector.
- Asahi Kasei aims for ¥150 billion in operating income by 2030
- The company focuses on expanding its pharmaceutical, life science, and critical care businesses.
Asahi Kasei Corp. (AHKSY, Financial) has announced the appointment of Ken Shinomiya as the new leader of its Healthcare Sector, succeeding Richard Packer. This strategic leadership change is expected to drive further growth in the company’s portfolio of pharmaceuticals, life sciences, and critical care products and services, enhancing its global presence in these fields.
With a strong background in strategic roles, Shinomiya previously served as Vice President of Strategy at ZOLL Medical Corporation and later became the head of the Bioprocess Division of Asahi Kasei Medical in 2019. His leadership of the life sciences business led to successful expansions, notably with the development of CRO testing services and the biologics CDMO business of Bionova Scientific in the U.S.
Since acquiring ZOLL Medical Corporation in 2012, Asahi Kasei’s Healthcare Sector has embraced globalization, with its headquarters moving to the U.S. in 2023. The sector's mission is to enhance patient outcomes through innovative therapeutics and medical devices, setting a target for operating income to reach ¥150 billion by 2030.
Commenting on his new role, Ken Shinomiya emphasized Asahi Kasei's century-old tradition of leveraging creativity and innovation to deliver superior products and services globally. He highlighted the company’s commitment to evolving with an international outlook and continuing to drive the growth of Asahi Kasei Group.
Asahi Kasei, recognized for its contributions to life and living since its establishment in 1922, continues to innovate across its sectors of Material, Homes, and Healthcare, striving towards a sustainable society and a carbon-neutral future by 2050.
